Pharma BD Deal Intelligence

Taiwan Tanabe Seiyaku Co., Ltd. / Energenesis Biomedical Co., Ltd.

2026 · Co-Development · Complete

Energenesis Biomedical and Taiwan Tanabe Seiyaku entered a joint development agreement announced August 6, 2026 covering ENERGI-F703DFU, Energenesis' investigational topical small-molecule gel for diabetic foot ulcers. The parties will collaborate on process technology transfer and CMC activities intended to support a potential NDA in Taiwan, and plan to advance discussions on future manufacturing and commercialization licenses for Taiwan and selected ASEAN markets under separate definitive agreements. ENERGI-F703DFU is in Phase 3 testing in Taiwan and the United States, with Phase 3 enrollment expected to complete in 2027. No financial terms were disclosed. Directionality note: the asset originates with Energenesis; prospective manufacturing and commercial rights in Taiwan/ASEAN flow to Taiwan Tanabe Seiyaku.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals